Dewpoint Therapeutics’ Post

View organization page for Dewpoint Therapeutics, graphic

10,957 followers

3mo

Exciting news! Dewpoint Therapeutics and Novo Nordisk have expanded their partnership to advance #drugdiscovery. By combining Dewpoint's high-throughput screening platform with Novo Nordisk's expertise in target discovery, the collaboration aims to unlock new therapeutic possibilities. Read the full update on our website: https://bit.ly/3RJyAiB

10 Comments

Ben Maddox

Consultant, Global Health Practice at Egon Zehnder

3mo

Congratulations Ameet and team

Mandeep Kaur MD, MS

3mo

Congratulations Ameet and Team!

1 Reaction

Rami Hannoush, Ph.D.

Healthcare Investor at Versant | Life sciences company creation | Former R&D leader, Genentech | co-Founder & Former CEO, EpiBiologics

3mo

Congrats Ameet Nathwani and Isaac Klein !! Great news.

1 Reaction

Md Abul Fazal

22K+Pharmaceutical Professionals connection Across the World.Pharma finished Products Exporter.Emergency patient support,Oncology, Hematology, Antiviral.

3mo

Great news! Congratulations 🎈

Matthias Evers

Biotech leader driving innovation through partnerships, tech, and strategy | Early-stage investor and advisor | DMs open for collaboration.

3mo

Congrats, Ameet Nathwani, and team!

Pascal Pfister MD.

3mo

Well done Ameet!

Naomi Muchiri

Global Engagement and Strategic Communications Advisor | Change Management Leader | Public Affairs and Media Relations Consultant | Crisis Management Consultant | Diversity, Equity, Inclusion and Accessibility Champion

3mo

Congratulations!

Dereck Amakye, MD FFPM

3mo

Congratulations!!!

Naomi Sutherland

Managing Partner for Boston office and advisory lead for Life Science

3mo

Congratulations!!

Anoop Nathwani

Forging Strategic Alliances For Growth Focused Businesses | High Level Coaching Programmes | Giving You A Competitive Advantage Through Transformative Change | CEO & Founder | Global Strategic Alliances & Partnerships

3mo

Congrats Ameet!

See more comments

To view or add a comment, sign in

More Relevant Posts

Jared Schuster, HTL(ASCP), CABP

Regulatory Scientist | Cell & Gene Therapies | Process & Analytical Development | CMC | Immunology | Infectious Diseases | Biomarkers
5mo
Report this post
Should be an engaging and insightful discussion! Looking forward to hearing from this esteemed panel. #allogeneic #celltherapy #celltherapymanufacturing #atmps #advancedtherapies #cellandgenetherapy
CASSS – Sharing Science Solutions

4,787 followers
5mo Edited

Session II of the CGTP Summit will discuss "Allogeneic Cell-based Therapies" with Julien Camperi, Genentech, a Member of the Roche Group, Jennifer Dashnau, PhD, MBA, Century Therapeutics, Inc, and Sangeetha Prakash, Takeda. Meet the speakers and register today. https://hubs.li/Q02wHKxw0 #casss #cgtpsummit2024 #cgt #celltherapy #genetherapy
Like Comment
To view or add a comment, sign in
Jacqueline Duarte, SPHR

Account Director
2mo
Report this post
To read the full report, click on the link in the original post comments

Instant Impact

88,467 followers
2mo Edited

Our latest BioPharma report found that companies have been heavily investing in operations over the past 12 months 📈 Ann Hargraves, Senior VP Human Resources at TScan Therapeutics, shares some additional insight around why operations is coming out on top as the fastest growing non-scientific skill. To read the full report, click on the link in the comments ⬇️
Like Comment
To view or add a comment, sign in
3D Executive Search Partners

668 followers
9mo
Report this post
Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics: The disease awareness and the emergence of new products in the pipeline will add to the focal segmental glomerulosclerosis market growth in the future. In addition, persistently rising cases of FSGS in the forecast period will contribute to the rise in the focal segmental...
Like Comment
To view or add a comment, sign in
Veranova

11,998 followers
3w
Report this post
ICYMI, Veranova’s Senior Vice President, Chief Technology Officer, Dr. Rohtash Kumar, recently contributed to a CHEManager International article focused on the future of the CDMO industry. In the article, Dr. Kumar shares his thoughts on the redefining of drug development timelines, as well as the increased demand for complex APIs and growing emphasis on patient-centricity. He also outlines how Veranova is expanding its capabilities and embracing innovation to respond to these trends and ensure it can continue supporting the delivery of life-changing therapeutics. Read the full article to learn more: https://lnkd.in/g2dzu8BS
Like Comment
To view or add a comment, sign in
Lucy Muniz

Editor/Founder The Pharmaceutical Marketing Group - Executive Director at Clinician Burnout Foundation
8mo
Report this post
While we have witnessed digital capabilities navigating the pharma through evolving landscape, the question in the realm of CGT remains - how much closer are we to demonstrating value using the universal language of data? Join senior leader from Sumitomo Pharma America, Microvascular Therapeutics, Mustang Bio and Bayer next month, to explore their visions on key trends shaping the future of CGT clinical development: https://bit.ly/3OkH4Ly
Like Comment
To view or add a comment, sign in
Grant Weinberg MCIPD
10mo
Report this post
Join our leaders at #jpm2024 and learn more about the work Eikon Therapeutics is focused on across the intersection of Science and Technology. #biotech #biotechcareers

Alfred (Freddie) Bowie

Chief Financial Officer at Eikon Therapeutics (We are hiring!)
10mo Edited

Thrilled to have a prime speaking slot at JPM! Look forward to meeting with the many investors, potential partners interested in the Eikon Therapeutics story and catching up with old friends. DM if interested in connecting with Eikon Therapeutics as we advanced a meaninfully derisked clinical portfolio. #jpm24

Eikon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

businesswire.com
Like Comment
To view or add a comment, sign in
Richard Staines

Account director, Optimum Strategic Communications
6mo
Report this post
Check out Optimum's latest podcast featuring an expert panel discussing the issue of diversity in clinical trial recruitment. Thanks to Germo Gericke, Annalisa Jenkins and John Maher for taking part!

Optimum Strategic Communications

1,838 followers
6mo

Diverse recruitment for #clinicaltrials is a huge issue – but what can drug developers do to overcome this challenge? Join Optimum Strategic Communications’ Richard Staines as he discuses this thorny issue with Ariceum Therapeutics CMO, Germo Gericke, Leucid Bio’s CSO, John Maher and Thought Leader Annalisa Jenkins. 📢 Listen to the latest episode of the #OptimumPerspectivesPodcast now: https://lnkd.in/eEwyCix9 #Ariceum #Leucidbio
Like Comment
To view or add a comment, sign in
Alcor Drug Discovery Platform (ADDP)

723 followers
6mo
Report this post
Excited to have Arkesh Mehta, Chairman & CEO of OncoBindi, Inc., at Day 2 of the Alcor Drug Discovery Platform! Join us for a compelling presentation on the NanoBindi-Platform for accelerated Therapeutics Development. Don't miss this opportunity to explore groundbreaking advancements in drug discovery! #AlcorDrugDiscovery #NanoBindi #TherapeuticsDevelopment #DrugDiscovery #Preclinical #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits
Like Comment
To view or add a comment, sign in
Hyungtaek Jason Jeon

Ph.D., Global Product Manager, BD, Xcell Therapeutics inc., Exosome, Virus, MSC, Chemically defined medium, Exosome isolation instrument, EXODUS
1mo Edited
Report this post
Interview of our CEO. His insights of chemically defined medium and CGT industry!
Cade Hildreth - BioInformant

BioInformant.com, World's Largest Publisher of Stem Cell News | Real Estate Investor | PatriotHoldings.com, Board Member, & Advisor | Former USA Rugby Player
1mo

Uri Lee, CEO of Xcell Therapeutics, on Being a Pioneer in Serum-free, Chemically Defined Media - https://lnkd.in/gkJU38TQ This is an interview with Uri Uiil Lee, CEO of Xcell Therapeutics (엑셀 세라퓨틱스). Xcell is an international leader in serum-free, chemically defined media. In this interview, we discuss the mission and purpose of Xcell Therapeutics, its product development pipeline, its rapid growth, and the company’s future goals. Enjoy. Read more at: https://lnkd.in/gkJU38TQ #msc #stemcell #mscmedia
Like Comment
To view or add a comment, sign in
Peter Böhm

Solution Oriented Critical Thinker / Working at the crossroad of clinic, operations, and business
5mo
Report this post
As more clinical trials in #Psychedelics emerge, it’s important to design studies with the patient’s condition in mind. Make sure to check out my team member’s presentation at the Psychedelic Therapeutics & Drug Development Conference to learn more! https://bit.ly/4bnRvXY

Presentation | Psychedelic Therapeutics & Drug Development Conference
Like Comment
To view or add a comment, sign in

10,957 followers

View Profile Follow

Dewpoint Therapeutics’ Post

More from this author

CONDENSATES: A bold vision for the origin and treatment of undruggable diseases — A conversation with Dewpoint CSO Dr. Isaac Klein

Explore topics